Biogen (BIIB) Call Leaves Tons of Questions, Priority Review Voucher Comment is Negative - Mizuho
Mizuho Securities analyst Salim Syed weighed on Biogen (NASDAQ: BIIB) saying the Q2 calls leaves room for tons of questions and the priority review voucher comment is telling, in a negative way.
Syed commented, "The Biogen 2Q call just finished and was interesting to say the least. There was no substantive commentary on CFO Jeff Capello's departure, which we find incredibly odd. And there was very little new commentary on the aducanumab front, but we believe the priority review voucher comment they made was extremely telling (in a negative way)."
The analyst reiterated a Neutral rating and $316.00 price target on BIIB.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $280.19 yesterday.